For good measure

Houston creatives relaunch nonprofit's brand through a 3-day collaboration

Allison Williams, who has been working with the Transformational Prison Project for two years, attended Good Measure to consult on the brand development. Alan Nguyen/Good Measure

What if you could harness the power of a city's top creative professionals to create a brand identity for a nonprofit that otherwise couldn't afford it? Alex Anderson posed that question to some of his colleagues, and Good Measure was born.

"Good Measure exists to broaden the conversation about good in the world and what that means and how people can contribute to good no matter their skill set," says Anderson, who is a senior brand strategist and account manager at Houston-based NUU Group.

Good Measure is a Houston-based nonprofit that hosts three-day creative collaborations with local designers, writers, brand strategists, and more. The goal is simple: Equip a nonprofit with new storytelling tools — like a website, social media, and video communicating the organization's message.

This weekend was the second event Anderson organized with his co-founder, Tres Garner. The nonprofit partner was the Transformational Prison Project, which uses restorative justice in Massachusetts prisons to help incarcerated individuals mindfully use their time in prison to create healing. It's about bringing everyone involved in the criminal justice system to the table to thoughtfully effect change and reinstate humanity in these prisons.

"The Transformational Prison Project understands that no matter what your position is within the criminal justice system that everybody is vulnerable to trauma. So, it's in everyone's vested interest to create more of a system that's reparative and healing than punitive." says Karen Lischinsky, director of TPP, in the teaser video created at Good Measure.

Lischinsky was a vital part of the weekend, as was actress Allison Williams (Girls and Get Out), who has been an advocate for TPP and has led restorative justice sessions in Massachusetts prisons for two years.

"I wish to transform the way that prisons, as we imagine them today, operate and the effects that they have on people," Williams says in the video.

Using their powers for good
Good Measure brought together 40 creatives — designers, developers, strategists, videographers, photographers, writers, stylists, and more — into NUU Group's East Downtown office to develop new branding, web design, and videography for TPP. Filming took place down the street at Primer Grey. Anderson says the point is to break down barriers and bring together individuals who would otherwise not get to work together.

"It's some feedback that we've heard over and over again how refreshing and inspiring it is to work with people across the city," Anderson says. "So, you get to come together and learn each other's processes and have a case study or portfolio piece with someone who's work you admire."

Good Measure volunteers work alongside the nonprofit partners, so Lischinsky and Williams were there every step of the way. It was a learning process for both sides of the equation — the volunteers making sure they understand and express the TPP's mission as well as TPP learning the importance of the brand development process. Anderson says Lischinsky's presence was key to the success of the weekend — as was Williams' who wasn't just a celebrity endorsement. Anderson says he could see her full heart was committed to the program.

"You pull in a celebrity figure, and there's a tactical play. It's advertising," he says. "But what was different about this event is that Allison is not a face. She showed up from the first day of Good Measure to participate and contribute as someone who is on the board of TPP and an advocate for the program."

Creating a movement
Good Measure is planning to double down on its efforts for a New York weekend early next year to serve two nonprofits with 100 creatives volunteering. The organization also expects to return to do another Houston weekend in 2019 as well as a collaboration in Los Angeles.

Anderson says they also plan on hosting a one-day conference in Houston to discuss social good. Williams and Lischinsky are both onboard to attend.

Doing the homework

Alan Nguyen/Good Measure

Actress Allison Williams and TPP Director Karen Lischinsky kicked off the three-day rebranding collaboration with a discussion focused on the organization's goals, challenges, and messaging.

Houston-based Moleculin has three different oncology technologies currently in trials. Getty Images

Immunotherapy and personalized medicine get all the headlines lately, but in the fight against cancer, a natural compound created by bees could beat them in winning one battle.

In 2007, chairman and CEO Walter Klemp founded Moleculin Biotech Inc. as a private company. The former CPA had found success in life sciences with a company that sold devices for the treatment of acne. That introduction into the field of medical technology pushed him toward more profound issues than spotty skin.

"Coincidentally, the inventor of that technology had a brother who was a neuro-oncologist at MD Anderson," Klemp recalls.

The since-deceased Dr. Charles Conrad slowly lured Klemp into what he calls the "cancer ecosphere" of MD Anderson. In 2016, the company went public. And it looks like sooner rather than later, it could make major inroads against some of the toughest cancers to beat.

Klemp observed that while Houston has the world's largest medical center, "the tragic irony" is that other cities have far more biotech money ready to be invested.

"The Third Coast is really starved for capital," he says. "What drew me into this was I was one of the few entrepreneurs that lived here that knew the ropes in terms of tapping into East and West Coast capital structures and could make that connection for them."

The company has three core technologies currently being tested with some success, but the most promising is called WP1066, named for researcher Waldemar Priebe, "a rock star" in his native Poland, according to Klemp, who works at MD Anderson. Though Priebe came to the U.S. in the 1980s, he is still an adjunct professor at the University of Warsaw and conducts some of his trials in Poland because it's easier to get grant money there.

WP1066 uses propolis, a compound of beeswax, sap and saliva that bees produce to seal small areas of their hives, as a base. The molecular compound that Priebe discovered affects STAT3 (signal transducer and activator of transcription), a transcription factor that encourages tumor development. In short, the active compound in WP1066 both downregulates the STAT3, a long-time Holy Grail in the cancer research world, and directly attacking the tumor, but also quieting T Cells, which allows the body's own immune system to fight the cancer itself. Essentially, it works both as chemotherapy and immunotherapy.

WP1066 is demonstrating drug-like properties in trials at MD Anderson on glioblastoma, the aggressive brain cancer that recently took the life of the hospital's former president, John Mendelsohn, as well as John McCain and Beau Biden. It is also being tested against pancreatic cancer, one of the most virulent killers cancer doctors combat.

Priebe also created Annamycin, named for his oldest daughter, a first-line chemotherapy drug that fights Acute Myeloid Leukemia without the cardiotoxicity that can damage patients' hearts even as they beat their cancer.

WP1122 uses yet another mechanism to fight cancer.

"Most people don't know that morphine is essentially a modified version of heroin," Klemp explains.

The difference between the poppy-based drugs? Heroin can cross the blood-brain barrier. It's described as the dicetyl ester of morphine. WP1122 is the dicetyl ester of 2DG (2-Deoxyglucose), a glycolysis inhibitor, which works by overfilling tumor cells with fake glucose so that they can't consume the real glucose that makes them grow.

"The theory is, we could feed you so full of junk food that eventually you'd starve to death," Klemp elucidates. It can cross the blood-brain barrier and is metabolized slowly, meaning that it can be made into a drug in a way that 2DG cannot.

What's impressive about Moleculin is its diversity of drugs. Most companies have one drug that gets all or most of the attention. Moleculin has strong hopes for all three currently in trials.

"It's essentially multiple shots on the goal," says executive vice president and CFO Jonathan Foster.

Moleculin has 13 total employees, five of whom are based in Houston. An office in the Memorial Park area serves as a landing pad for employees and collaborators from around the world to get their work done when in Space City. The virtual office set-up works for the company because experts can stay in their home cities to get their work done. And that work is on its way to saving scores of lives.